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WS20.1 Role of transcription factors and microRNAs in CFTR gene
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1INSERM U827, Montpellier, France; 2Universite´ Montpellier 1, Montpellier,
France; 3CHRU Montpellier, Montpellier, France
Objectives: CFTR gene, described as a housekeeping gene, displays a tightly
temporal and developmental regulation. In lung, CFTR transcripts are abundant
during fetal compared to adult stage, where only two copies per cell are detected.
The aim of this work is the characterization of regulatory elements acting on the
amount of CFTR transcripts (transcription and stability) to explain the regulation
of CFTR gene expression in lung.
Methods: 3′UTR and 5′UTR regions of CFTR gene were analysed thanks to
bioinformatics tools (TS Search, Consite, AREsite, miRBase). To evaluate the
importance of each predicted motif for transcription factors (FTs) and microRNAs
(miRNAs), functional studies were realized (Luciferase assays, siRNA, RTq-PCR,
constructions containing or not degenerated motifs for trans-regulators. . . ). Based
on the identiﬁcation of miRNAs binding sites on CFTR mRNA, we also propose to
test new potential therapeutic tools for CF patients by designing oligonucleotides
TSB (Target Site Blockers).
Results: We characterized new motifs for the binding of FTs on CFTR mRNA,
key regulators in the pulmonary development (FOX, C/EBP, Nkx2), and miRNAs
(miR101, miR145) explaining the modulation of CFTR transcrits rate in lung. In
addition, the ﬁrst ﬁndings on the use of oligonucleotides TSB led to increased of
CFTR mRNA and protein level in CF patients.
Conclusion:We propose a molecular network involving FTs and miRNAs to explain
difference in the CFTR transcrit level, in fetal and adult lungs. Identiﬁcation of cis-
regulatory motifs led to envision new tools for CF therapy.
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WS20.2 Over-expression of miR-494 and miR-145 correlates with
CFTR and SMAD3 down-regulation in cystic ﬁbrosis patients
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Objectives: microRNAs (miRNAs) have recently been emerged as important regu-
latory molecules in Cystic Fibrosis (CF) disease in which airways tissues/organs are
often characterized by severe inﬂammation and infections. In order to comprehend
the role of miRNAs in the CF pathogenesis, we analyzed the expression of speciﬁc
miRNAs in nasal epithelia of CF patients and healthy controls.
Methods: Quantitative real time PCR (Q-PCR) showed that both miR-145 and
miR-494 were signiﬁcantly up-regulated in nasal epithelial tissues from CF patients
compared with healthy subjects (p< 0.001 and p< 0.01, respectively). Only miR-
494 levels correlated with a reduced CFTR mRNA expression (r = −0.42, p< 0.05,
Pearson’s correlation), supporting the negative regulatory role of this miRNA on
CFTR synthesis. Using customized bioinformatic pipelines, we identiﬁed SMAD3,
a key element of the TGF-beta1 inﬂammatory pathway, as a putative target of
miR-145. Indeed, luciferase reporter assays showed that miR-145 synthetic mimics
suppressed by approximately 40% the expression of a reporter construct containing
the SMAD3 3′-untranslated region. In addition, we observed an inverse correlation
between SMAD3 mRNA expression and miR-145 in CF nasal tissues (r = −0.68,
p< 0.001, Pearson’s correlation).
Conclusion: Our data conﬁrm the importance of miRNAs in the CF pathogenesis
and suggest that miRNA deregulation plays a role in the airway disease severity
by modulating CFTR levels as well as the expression of molecules involved in
the inﬂammatory response. Therefore, miR-494 and miR-145 may be not only
novel biomarkers but also potential tools in order to target speciﬁc CF clinical
manifestations.
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Microarray studies of cystic ﬁbrosis (CF) airway gene expression have made little
progress in deﬁning a robust molecular signature associated with F508del-CFTR
expression. Differences in platform and experimental design have led to widely
differing conclusions [1].
We carried out a whole genome microarray study of gene expression in human
native nasal epithelial cells from F508del-CFTR homozygotes and non-CF controls.
Superﬁcial comparison of our data with ﬁve other published microarray datasets
showed that the number of differentially expressed genes shared between indepen-
dent studies was often no greater than that expected by chance. To reduce underlying
methodological variability we therefore performed a more in-depth meta-analysis
of our dataset alongside two other CF studies using only native airway tissue
samples [2,3], which allowed us to compare data from bronchial and nasal tissues,
and from patients with mild and severe CF. For this analysis we developed a novel
statistical methodology based on a permutation test.
We conclude that independent studies of in vivo gene expression provide interesting
clues to CF pathogenesis based on the signiﬁcant differential expression of a few
key genes. However, detection of a consistent molecular signature by comparison
of datasets obtained in different platforms remains elusive.
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UI0006/2011 (CEAUL).
Reference(s)
[1] Hampton TH, Stanton BA (2010). Am J Physiol Lung Cell Mol Physiol298:
L473−82.
[2] Wright JM et al (2006). Am J Respir Cell Mol Biol 35: 327−36.
[3] Ogilvie V et al (2011). Genomics 98: 327−36.
WS20.4 The rs1078761 polymorphism is associated with reduced
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Objectives: A genome-wide association study of CF modiﬁer genes identiﬁed the
rs1078761 polymorphism (MAF = 0.310) in the 20q11 region as a marker associated
with lung disease severity (p = 1.3x10−4). The identiﬁed region contains two genes,
LPLUNC1 and SPLUNC1, which are proposed to play a role in innate immunity
in the lungs. We hypothesized that the G allele of rs1078761, which is associated
with more severe disease, reduces expression of the SPLUNC1 and/or LPLUNC1
genes, resulting in an impaired immune response in CF patients.
Methods: mRNA expression was measured in peripheral lung sections from
genotyped CF and non-CF patients using quantitative PCR (100 patients) and
microarray analysis (1111 patients). Saliva samples were collected and genotyped
from 55 healthy volunteers. Western blotting and ELISA were used to measure
protein levels in lung and saliva samples.
Conclusions: LPLUNC1 and SPLUNC1 had 8 and 30 fold higher levels of
mRNA expression, respectively, in CF lung samples compared to non-CF samples
(p< 0.0001). The G allele of rs1078761, which was associated with increased CF
severity, was associated with lower mRNA levels of SPLUNC1 but not LPLUNC1
in CF (p = 0.0181) and non CF lungs (p = 0.0086). Although rs1078761 was not
signiﬁcantly associated with SPLUNC1 protein levels in saliva or lung tissue
(p = 0.3767 and 0.2382, respectively) there was a trend towards reduced SPLUNC1
protein with the G allele. Preliminary data show that recombinant SPLUNC1
reduced growth of P. aeruginosa in a dose dependent manner. Therefore, low levels
of SPLUNC1 may be detrimental to the immune response in CF and SPLUNC1
may be an important target for augmentation therapy.
